PIK3C3 and cancer: As further confirmation, a pharmacological approach based on PIK-III and SAR405, two specific inhibitors for PIK3C3/Vps34, a lipid kinase controlling autophagosome formation, revealed that inhibition of autophagy increases CDDP efficacy in resistant cancer cells.